Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome.

OBJECTIVE To measure, and seek clinical correlates with, levels of substance P (SP) in the cerebrospinal fluid (CSF) of fibromyalgia syndrome (FMS) patients. METHODS CSF from 32 FMS patients and 30 normal control subjects was tested for SP by radioimmunoassay. Clinical measures included tender point examination and standardized questionnaires. RESULTS CSF SP levels were 3-fold higher in FMS patients than in normal controls (P < 0.001), but they correlated only weakly with tenderness found on examination. CONCLUSION SP is significantly elevated in FMS CSF, but other abnormalities must exist in FMS to more fully explain the symptoms.

[1]  M. Yunus,et al.  Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. , 1981, Seminars in arthritis and rheumatism.

[2]  D. Price,et al.  Evidence that substance P selectively modulates C-fiber-evoked discharges of dorsal horn nociceptive neurons , 1990, Brain Research.

[3]  M. Piercey,et al.  Morphine does not antagonize the substance P mediated excitation of dorsal horn neurons , 1980, Brain Research.

[4]  M. Roberts,et al.  Responses of spinal neurones to a substance P analogue, noxious pinch and bradykinin. , 1980, European Journal of Pharmacology.

[5]  A. Malmberg,et al.  Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. , 1992, Science.

[6]  R. Coggeshall,et al.  Peptide immunoreactivity of unmyelinated primary afferent axons in rat lumbar dorsal roots. , 1989, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[7]  R. Dubner,et al.  Spatial and temporal transformations of input to spinothalamic tract neurons and their relation to somatic sensations. , 1978, Journal of neurophysiology.

[8]  R. Dubner,et al.  Trigeminothalamic neurons in nucleus caudalis responsive to tactile, thermal, and nociceptive stimulation of monkey's face , 1976 .

[9]  K. Marshall,et al.  Substance P and arthritis: analysis of plasma and synovial fluid levels. , 1990, Arthritis and rheumatism.

[10]  H. Takagi,et al.  Met-enkephalin and morphine but not dynorphin inhibit noxious stimuli-induced release of substance P from rabbit dorsal horn in situ , 1985, Neuropharmacology.

[11]  M. Yunus,et al.  Electron microscopic studies of muscle biopsy in primary fibromyalgia syndrome: a controlled and blinded study. , 1989, The Journal of rheumatology.

[12]  Y. de Koninck,et al.  Spinal neurons exhibiting a specific nociceptive response receive abundant substance P-containing synaptic contacts. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[13]  F. Wolfe.  The Epidemilogy of Fibromyalgia , 1993 .

[14]  I. Russell,et al.  Psychological stress and the fibrositis/fibromyalgia syndrome. , 1990, The Journal of rheumatology.

[15]  L. Terenius,et al.  No evidence for endorphin deficiency in fibromyalgia following investigation of cerebrospinal fluid (CSF) dynorphin A and Met-enkephalin-Arg6-Phe7 , 1991, Pain.

[16]  J. Harvey,et al.  Behavioral correlates of serotonin depletion. , 1975, Federation proceedings.

[17]  R. Bennett,et al.  Clinical characteristics of fibrositis. I. A "blinded," controlled study of symptoms and tender points. , 1983, Arthritis and rheumatism.

[18]  J. Fries,et al.  Survival, prognosis, and causes of death in rheumatoid arthritis. , 1986, Arthritis and rheumatism.

[19]  S. Folkman,et al.  The impact of daily stress on health and mood: psychological and social resources as mediators. , 1988, Journal of personality and social psychology.

[20]  M. Matucci-Cerinic,et al.  Substance P and Somatostatin Levels in Rheumatoid Arthritis, Osteoarthritis, and Psoriatic Arthritis Synovial Fluid , 1991, Annals of the New York Academy of Sciences.

[21]  H. Frenk,et al.  Is substance P a primary afferent neurotransmitter for nociceptive input? III. Valproic acid and chlordiazepoxide decrease behaviors elicited by intrathecal injection of substance P and excitatory compounds , 1988, Brain Research.

[22]  P. Tugwell,et al.  The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee. , 1990, Arthritis and rheumatism.

[23]  R. González-Amaro,et al.  One thousand private rheumatology patients in Mexico City. , 1983, Arthritis and rheumatism.

[24]  I. Russell,et al.  Is there a metabolic basis for the fibrositis syndrome? , 1986, The American journal of medicine.

[25]  M. Cohen,et al.  Abnormal responses to electrocutaneous stimulation in fibromyalgia. , 1993, The Journal of rheumatology.

[26]  F. Wolfe,et al.  Prevalence of primary and secondary fibrositis. , 1983, The Journal of rheumatology.

[27]  J. Henry,et al.  Effects of substance P on functionally identified units in cat spinal cord , 1976, Brain Research.

[28]  R. Inman,et al.  Plasma substance P levels in fibrositis. , 1988, The Journal of rheumatology.

[29]  H. Takagi,et al.  Effects of morphine on noxious stimuli-induced release of substance P from rabbit dorsal horn in vivo. , 1983, Life sciences.

[30]  F. Wolfe,et al.  Functional ability and work status in patients with fibromyalgia , 1988 .

[31]  H. Frenk,et al.  Is substance P a primary afferent neurotransmitter for nociceptive input? I. Analysis of pain-related behaviors resulting from intrathecal administration of substance P and 6 excitatory compounds , 1988, Brain Research.

[32]  W. K. Slack,et al.  HYPERBARIC OXYGENATION CHRONIC OSTEOMYELITIS. , 1965, The Lancet.

[33]  L. Terenius,et al.  Characterization of a substance P-Gly12 amidating enzyme in human cerebrospinal fluid. , 1987, Biochemical and biophysical research communications.

[34]  D. Laskin,et al.  A Biochemical Measure of Stress in Patients with Myofascial Pain-Dysfunction Syndrome , 1972, Journal of dental research.

[35]  G. Riddoch.  THE CLINICAL FEATURES OF CENTRAL PAIN , 1938 .

[36]  L. Terenius,et al.  Cerebrospinal fluid levels of beta-endorphin in patients with fibromyalgia (fibrositis syndrome). , 1988, The Journal of rheumatology.

[37]  Russell Ij.  Neurohormonal aspects of fibromyalgia syndrome. , 1989 .

[38]  M. Randić,et al.  Effect of substance P in cat dorsal horn neurones activated by noxious stimuli , 1977, Brain Research.

[39]  W. Zung.  A SELF-RATING DEPRESSION SCALE. , 1965, Archives of general psychiatry.

[40]  I. Isdale,et al.  The loose back: an unrecognized syndrome. , 1971, Rheumatology and physical medicine.

[41]  H. Frenk,et al.  Is substance P a primary afferent neurotransmitter for nociceptive input? IV.2-Amino-5-phosphonovalerate (APV) and [d-Pro2, d-Trp7,9]-substance P exert different effects on behaviors induced by intrathecal substance P, strychnine and kainic acid , 1988, Brain Research.

[42]  L. Terenius,et al.  Substance P in CSF of patients with chronic pain syndromes , 1988, Pain.

[43]  O. Igwe,et al.  Role of Substance P Amino Terminal Metabolites in Substance P-Induced Desensitization in Mice , 1990, Neuroscience.

[44]  I. Russell,et al.  Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. , 1991, Arthritis and rheumatism.

[45]  H. Frenk,et al.  Is substance P a primary afferent neurotransmitter for noniceptive input? II. Spinalization does not reduce and intrathecal morphine potentiates behavioral responses to substance P , 1988, Brain Research.

[46]  A. Russell,et al.  Hypothalamic response in rheumatoid arthritis: does it justify the use of steroids? , 1993, Arthritis and rheumatism.

[47]  A. Fischer,et al.  Pressure Threshold Measurement for Diagnosis of Myofascial Pain and Evaluation of Treatment Results , 1986 .

[48]  J. Rı́o,et al.  Long-lasting neurochemical and functional changes in rats induced by neonatal administration of substance P antiserum , 1989, Brain Research.

[49]  I. Russell,et al.  Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. , 1992, The Journal of rheumatology.

[50]  L. Terenius,et al.  Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: new features for diagnosis , 1988, Pain.

[51]  Jacob Cohen.  Statistical Power Analysis for the Behavioral Sciences , 1969, The SAGE Encyclopedia of Research Design.

[52]  F. Wolfe,et al.  Fibrositis: symptom frequency and criteria for diagnosis. An evaluation of 291 rheumatic disease patients and 58 normal individuals. , 1985, The Journal of rheumatology.

[53]  L. Radloff.  The CES-D Scale , 1977 .

[54]  M. Kirby,et al.  Increase in substance P in the dorsal horn during a chemogenic nociceptive stimulus , 1985, Brain Research.

[55]  A. Blomqvist,et al.  Neonatal exposure to substance P alters behavioral and substance P levels in the central nervous system of the adult rat. , 1991, Brain research. Developmental brain research.

[56]  G. A. Mccain,et al.  The Effects of Changing the Painful Stimulus upon Dolorimetry Scores in Patients with Fibromyalgia , 1993 .